In the wake of another pair of high-profile suicides, observers of the pharmaceutical industry and healthcare providers say the need for new treatment options for depressed people couldn't be more apparent.
With shocked fans still mourning the death of Anthony Bourdain, the spike in suicides since the beginning of the century clearly illustrate there is a problem with the medications we are currently reliant on, according to Harry Tracy of newsletter Neuroperspectives.
“Psychiatry has become a disfavored area for investment,” he told Reuters. “Insurers say ‘why should we pay more for a new treatment?’”
Currently, pharmaceutical companies have 140 therapies in development targeting mental health issues, 39 of which are aimed at depression. Compared with work being done on 1,100 experimental cancer drugs – which generally fetch a much higher price – and a clearer picture of the problem emerges.